Publications
2008
Cano SJ, Hobart JC. Watch out, watch out, the FDA are about. Developmental Medicine & Child Neurology 2008, 50: 408-409.
Hagell P, Törnqvist AL, Hobart JC. Testing the SF-36 in Parkinson’s disease:
implications for reporting rating scale data. Journal of Neurology 2008 Jan 22; [Epub ahead of print]
Hirst CL, Pace A, Pickersgill TP, Jones R, McLean BN, Zajicek JP, Scolding NJ, Robertson NP. Campath 1-H Treatment in Patients with Aggressive Relapsing Remitting Multiple Sclerosis. J Neurol 2008. In press.
Hosking RD, Zajicek JP. Therapeutic potential of cannabis in pain medicine. Br J Anaesth. 2008 Jul;101(1):59-68.
Zajicek J. Disease modifying treatments in Multiple sclerosis. European Neurological Disease 2008. In press.
2007
Campbell J, Winder R, Richards SH, Hobart JC. Exploring the relationships between provision of welfare benefits advice and the health of older people: a longitudinal observational study and discussion of methodological issues. Health and Social Care in the Community 2007 Sep; 15(5):454-63.
Cano SJ, Thompson AJ, Bhatia K, Fitzpatrick R, Warner TT, Hobart JC. Evidence-based guidelines for using the Short Form 36 in cervical dystonia. Movement Disorders 2007; 22(1); 122-126.
Hobart JC. Measuring outcomes in clinical trials of stroke: time for state-of-the-art clinical trials to reject state-of-the-ark rating scales. Journal of Neurology 2007; 254(8):1119 (Invited commentary).
Hobart JC, Cano SJ, Zajicek JP, Thompson AJ. Rating scales as outcome measures for clinical trials in neurology: problems, solutions and recommendations. Lancet Neurol. 2007, 6: 1094-105.
Katzenschlager R, Schrag A, Manson A, Evans A, Carroll CB, Lees AJ, Hobart JC. Quantifying the impact of dyskinesias in Parkinson’s disease: the PDYS-26. Neurology 2007 Aug 7; 69(6):555-63.
Richardson SJ, Widmer M, Zajicek J, Rule SA. Physiological doses of cannabinoids do not adversely affect Mantle cell lymphoma cell viability. (letter) Leukaemia and Lymphoma, 2007, 48: 1855-7.
Schrag A, Selai C, Mathias C, Low P, Hobart JC, Quinn NP. Measuring health related quality of Life in MSA: The MSA-QoL. Movement Disorders 2007; 22(16) :2332-8.
Zajicek J. The epidemiology of multiple sclerosis (editorial). J Neurol. 2007, 254: 1742.
Zajicek J, Collingbourne J, Freeman J. Handbook of Multiple Sclerosis Oxford University Press, 2007.
2006
Adekanmi O, Freeman R, Waterfield M, Waterfield A, Bishop R, Zajicek J. The Effect of Cannabinoids on Lower Urinary Tract Symptoms in Multiple Sclerosis: a randomised placebo controlled trial (CAMS-LUTS). Accepted for publication by the International Urogynecology Journal, 2006.
Baron R, Elashaal R, Germon T, Hobart JC. Measuring the outcomes of cervical spine surgery: think twice before using the SF-36? Spine 2006; 31 (22): 2575 - 2584.
Cano SJ, Hobart JC, Edwards M, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology. 2006 Dec 26; 67(12):2230-2.
Cano SJ, OConnor RJ, Thompson AJ, Hobart JC. Exploring disability rating scale responsiveness II: do more response options help? Neurology 2006; 67(11): 2056-2059.
Chataway JC, Porter B, Heaney D, Riazi A, Watt H, Hobart JC, Thompson, AJ. Treating multiple sclerosis relapses at home or in hospital out-patients: a randomised controlled trial of intravenous steroid delivery. Lancet Neurology. 2006 Jul; 5(7):565-71.
Hobart JC. Handbook of Neurological Rating Scales. (Book Review). Journal of Neurology, Neurosurgery and Psychiatry 2006; 77: 1298.
Hobart JC, Riazi A, Thompson AJ, Styles IM, Fox PJ, Ingram WM, Warner M, Vickery PJ, Zajicek JP. Getting the measure of spasticity in MS: the MS Spasticity Scale (MSSS-89). Brain 2006; 129: 224-234.
Holland A, O’Connor R J, Thompson AJ, Playford ED, Hobart JC. Talking the talk on walking the walk: a 12-item generic walking scale for neurological conditions. Journal of Neurology 2006 Aug 21; [Epub ahead of print]
Riazi A, Cano SJ, Cooper JM, Bradley JL, Schapira AHV, Hobart JC. Coordinating outcomes measurement in ataxia research: do existing scales tick the boxes? Movement Disorders 2006; 21(9):1396-403
Schrag A, Selai C, Quinn N, Lees AJ, Litvan I, Lang A, Poon Y, Bower J, Burn D, Hobart JC Measuring Quality of Life in PSP: The PSP-QoL.Neurology.2006 Jul 11; 67(1):39-44.
van der Linden FAH, Kragt JJ, Hobart JC, M Klein M, Thompson AJ, van der Ploeg HM, Polman CH, Uitdehaag BMJ. Proxy measurements in Multiple Sclerosis: agreement between patients and their partners on the impact of MS in daily life. Journal of Neurology, Neurosurgery and Psychiatry 2006; 77: 1157-1162.
2005
Schrag A, Selai C, Quinn N, Hobart J. Measuring health-related quality of life in patients with progressive supranuclear palsy. Neurocase. 2005 Aug;11(4):246-9.
Freeman JA, Hobart JC, Playford ED, Undy B, Thompson AJ. Evaluating neurorehabilitation - lessons from routine data collection. Journal of Neurology, Neurosurgery, and Psychiatry 2005 May; 76(5):723-8.
Carroll CB, Hilton DA, Hamon M, Zajicek JP Muscle Cramps and Weakness Secondary to Graft versus Host Disease Fasciitis Eur J Neurol 2005, 12: 320-5.
Liu X, Carroll C, Wang S-Y, Zajicek J, Bain P. Quantifying drug-induced dyskinesias in the arms using digitised spiral-drawing tasks. J Neurosci Methods 2005, 144: 47-52.
Zajicek J, Fox P, Teare L, Sanders H, Wright D, Vickery J, Ingram W, Reilly S, Nunn A, Thompson A. Cannabinoids in multiple sclerosis (CAMS) study, safety and efficacy data from up to 12-months follow-up. J Neurol Neurosurg Psychiatry 2005, 76: 1664-9.
Katona S, Kaminski E, Sanders H, Zajicek J. Cannabinoid effects on cytokine profile in multiple sclerosis. Clin Exp Immunol 2005, 140: 580-585.
Zajicek J. Diagnosis and disease modifying treatments in multiple sclerosis, a review. Postgraduate Medical Journal 2005, 81: 556-561.
Teare L, Zajicek J. The Use of Cannabinoids in Multiple Sclerosis. Exp Opin Invest Drugs 2005, 14: 859-869.
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with other self-report scales. Journal of Neurology, Neurosurgery, and Psychiatry 2005; 76 (11): 1539-1543.
Cano SJ, Hobart JC, Hart PE, Korlipara LVP, Schapira AVH, Cooper JM. International Co-operative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's Ataxia? Movement Disorders 2005; 20(12): 1585-1591.
Nicholl L, Hobart JC, Dunwoody L, Cramp F, Lowe-Strong A. Measuring quality of life in MS is not as easy as it sounds. Multiple Sclerosis 2005 11(6): 708-712.
Hobart JC. How severe is chronic pain in multiple sclerosis? Nature Clinical Practice Neurology 2005;1(2):80-81. [a peer reviewed commissioned commentary].
2004
Hobart JC, Kalkers NF, Barkhof F, Uitdehaag CMJ, Polman CH, Thompson AJ. Outcome measures for MS clinical trials: relative measurement precision of EDSS and MS functional composite. Multiple Sclerosis 2004; 10: 41-46.
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based outcome measure. Health Technol Assess. 2004; 8(9): 1-60.
Riazi A, Thompson AJ, Hobart JC. Self-efficacy predicts self-report health status in MS. Multiple Sclerosis 2004; 10: 61-66.
Carroll C, Hobart JC, Teare L, Scarpelli K, Gibson J. Stroke in Devon: knowledge is good but action is poor. Journal of Neurology, Neurosurgery, and Psychiatry 2004; 75: 567-571.
Cano SJ, Hobart JC, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT. Patient-based outcomes of cervical dystonia: a review of the rating scales. Movement Disorders 2004; 19(9): 1054-1059.
L Nicholl, J Hobart, L Dunwoody, F Cramp, A Lowe-Strong. Measuring Disability in Multiple Sclerosis: is the Community Dependency Index an Improvement on the Barthel Index? Multiple Sclerosis 2004; 10: 447-450.
Fox CM, Bensa S, Bray I, Zajicek JP. The epidemiology of multiple sclerosis in Devon: a comparison of the new and old classification criteria. J Neurol Neurosurg Psychiatry 2004 75: 56-60.
Carroll C, Zajicek JP. Meeting the ABN guidelines: provision of 24-hour acute neurology care by neurologists. J Neurol Neurosurg Psychiatry 2004, 75: 406-9.
Carroll CB, Bain P, Teare L, Liu X, Joint C, Wroath C, Parkin S, Fox P, Wright D, Hobart J, Zajicek J. Cannabis for Dyskinesia in Parkinson Disease: a Randomised Double-blind Crossover Study. Neurology 2004; 63: 1245-50.
Fox P, Carroll C, Glickman S, Bain PG, Zajicek J. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology. 2004, 62: 1105-1109.
Carroll CB, Zajicek JP The 'Harlequin' Sign in Association with Multiple Sclerosis. J Neurol 2004; 251: 1145-6.
2003
Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, UK MS Research Group. The use of cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis - results of a multicentre randomised placebo-controlled trial (the CAMS study). Lancet 2003, 362: 1517-26.
Hobart JC, Fitzpatrick R, Freeman JA, Thompson AJ. Socio-demographic variables are limited predictors of health status in MS. Journal of Neurology 2003; 9:1088-1093.
Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ. Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales. Multiple Sclerosis 2003; 9:411-419.
Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Freeman JA, Jenkinson C, Peto V, Thompson AJ. Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profile. Journal of Neurology, Neurosurgery and Psychiatry 2003;74:710-714.
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. Measuring the impact of MS on walking ability: the 12-item MS walking scale (MSWS-12). Neurology 2003;60:31-36.
2002
Mazza G, Ponsford M, Lowrey P, Campbell MJ, Zajicek J, Wraith DC. Diversity and dynamics of the T-cell response to MBP in DR2+ve individuals. Clin Exp Immunol. Jun 2002;128(3):538-47.
Hobart JC, Williams LS, Moran K, Thompson AJ. Quality of life measurement after stroke: uses and abuses of the SF-36. Stroke 2002; 33:1348-1356.
Hobart JC. Measuring disease impact in disabling neurological conditions. Are patients' perspectives and scientific rigor compatible? Current Opinion in Neurology 2002; 15(6):721-724.
Zajicek J, Fox P. Recent clinical trials failures in MS. International MS Journal 2002, 8; 97- 103.
Fox P, Zajicek J. Cannabis for multiple sclerosis. Practical Neurology 2002; 2: 154-160.
Vinogradova I. M., Zajicek J., Gentile S., Brown E. R. Effect of glycine on synaptic transmission at the third order giant synapse of the squids Alloteuthis subulata and Loligo vulgaris. Neuroscience Letters 2002; 325: 42-46.
Zajicek J., (2002) Cannabinoids on trial for multiple sclerosis. Lancet Neurology 1: 147.
2001
Hobart JC, Lamping DL, Freeman JA, Langdon DW, McLellan DL, Greenwood RJ, Thompson AJ. Evidence-based measurement: which disability scale for neurological rehabilitation? Neurology 2001; 57:639-644.
Hobart JC, Lamping DL, Fitzpatrick R, Riazi A, Thompson AJ. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001;124:962-973.
Ponsford M., Mazza G., Coad J., Campbell M. J., Zajicek J., Wraith D. C. Differential responses of CD45+ve T-cell subsets to MBP in multiple sclerosis. Clin. Exp. Immunol. 2001, 124; 315-22.
Craner M., Zajicek J. Immunosuppressive treatments in MS - side